Showing results (101-110 of 118) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11Michael D Jain, David B Miklos, Caron A Jacobson, et al.Cell Calcium|November 28, 2025
Fura-10, unlike fura-2, is suitable for long-term calcium imaging in natural killer (NK) cells without compromising cytotoxicity and can be combined with target cell death analysisLea Kaschek, Joanne Vialle, Gebhard Stopper, et al.JAMA Oncology|July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical TrialAnimesh Pardanani, Claire Harrison, Jorge E Cortes, et al.Leukemia|June 30, 2018
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targetingLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.Plos One|September 7, 2022
Your best day: An interactive app to translate how time reallocations within a 24-hour day are associated with health measuresDorothea Dumuid, Timothy Olds, Melissa Wake, et al.Scandinavian Journal of Gastroenterology|September 17, 2005
Time-trends in the epidemiology of peptic ulcer bleedingChristian Ohmann, Michael Imhof, Christian Ruppert, et al.Journal of Translational Autoimmunity|November 25, 2022
Autoantibodies against SUMO1-DHX35 in long-COVIDLorenz Thurner, Natalie Fadle, Evi Regitz, et al.European Journal of Immunology|March 31, 2021
Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patientsIgor Kos, Benedikt Balensiefer, Vadim Lesan, et al.American Journal of Cancer Research|July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphomaTom van Meerten, John Kuruvilla, Kevin W Song, et al.Molecular Cancer|September 28, 2024
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patientsSylvia Zöphel, Nadja Küchler, Johanna Jansky, et al.Pageof 12